• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Abivax SA - American Depositary Shares (NQ:ABVX)

    72.50 -57.19 (-44.10%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 16,049,377
    Open 77.53
    Bid (Size) 74.10 (100)
    Ask (Size) 75.00 (1,300)
    Prev. Close 129.69
    Today's Range 69.81 - 83.34
    52wk Range 5.690 - 148.83
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Keep an eye on the top gainers and losers in Tuesday's session. ↗
    Via Chartmill
    These stocks are moving in today's session ↗
    Via Chartmill

    Performance

    YTD
    -45.8%
    -45.8%
    1 Month
    -38.1%
    -38.1%
    3 Month
    -35.9%
    -35.9%
    6 Month
    -39.5%
    -39.5%
    1 Year
    +1041.7%
    +1041.7%

    More News

    Read More
    Tuesday's session: gap up and gap down stocks ↗
    Via Chartmill
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    Which stocks are moving after the closing bell on Monday? ↗
    Via Chartmill
    News headline image
    Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
    From Abivax
    Via GlobeNewswire
    News headline image
    Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
    From Abivax
    Via GlobeNewswire
    News headline image
    2 Stocks That Could Realistically Double by 2030 ↗
    Via The Motley Fool
    News headline image
    Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
    Via The Motley Fool
    News headline image
    Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
    Via The Motley Fool
    Topics ETFs Regulatory Compliance
    News headline image
    What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗
    Via The Motley Fool
    News headline image
    Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
    Via The Motley Fool
    News headline image
    Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Abivax Announces Results of its May 11, 2026 Annual General Meeting
    From Abivax
    Via GlobeNewswire
    News headline image
    Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
    From Abivax
    Via GlobeNewswire
    News headline image
    Abivax to Present Data on Obefazimod at Digestive Disease Week®
    From Abivax
    Via GlobeNewswire
    News headline image
    Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
    From Abivax
    Via GlobeNewswire
    News headline image
    This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy? ↗
    Via The Motley Fool
    News headline image
    Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
    From Abivax
    Via GlobeNewswire

    Frequently Asked Questions

    Is Abivax SA - American Depositary Shares publicly traded?
    Yes, Abivax SA - American Depositary Shares is publicly traded.
    What exchange does Abivax SA - American Depositary Shares trade on?
    Abivax SA - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Abivax SA - American Depositary Shares?
    The ticker symbol for Abivax SA - American Depositary Shares is ABVX on the Nasdaq Stock Market
    What is the current price of Abivax SA - American Depositary Shares?
    The current price of Abivax SA - American Depositary Shares is 72.50
    When was Abivax SA - American Depositary Shares last traded?
    The last trade of Abivax SA - American Depositary Shares was at 06/02/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.